Novo Nordisk in short
Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries.
Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
A passion for helping people
The story of Novo Nordisk goes back more than 80 years. It began when August Krogh, a Nobel Prize-winning professor at the University of Copenhagen, decided he wanted to start producing a revolutionary new medical preparation called insulin.
Our business philosophy
The Triple Bottom Line -
In practice, this means that any decision should always seek to combine three considerations: is it financially, socially and environmentally responsible? This way, we continuously optimise our business performance and enhance our contribution to the societies we operate in.
Facts and figures
Affiliates or offices in 75 countries
Approximately 40,700 employees (September 2014)
Growth hormone therapy
Hormone replacement therapy
More facts and figures here
Novo Nordisk A/S
Novo Allé, 2880 Bagsvaerd